A phase II clinical trial of idarubicin administered to children with relapsed brain tumors

Cancer

Volumn 83, Issue 4, 1998, Pages 813-816

  Arndt, Carola A S ^a,b   Krailo, Mark D ^b   Steinherz, Laurel ^c   Scheithauer, Berndt ^a   Liu Mares, W ^b   Reaman, Gregory H ^d  

^a MAYO CLINIC   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Astrocytoma; Brain tumors; Brainstem tumor; Children; Ependymoma; Idarubicin; Medulloblastoma

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER RECURRENCE; CARDIOTOXICITY; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG PENETRATION; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEDULLOBLASTOMA; PRIORITY JOURNAL;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; ASTROCYTOMA; BRAIN NEOPLASMS; BRAIN STEM; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; EPENDYMOMA; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IDARUBICIN; INFANT; INFUSIONS, INTRAVENOUS; MALE; MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL;

EID: 0031812626     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980815)83:4<813::AID-CNCR27>3.0.CO;2-U     Document Type: Article

References (17)

1. Casazza AM, Pratesi G, Giuliani F, De Marco A. Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 1990; 66:549-64.
2. Arcamone F, Bernardi L, Giardino P, Patelli B, Di Marco A, Casazza A, et al. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their B anomers. Cancer Treat Rep 1976;60:829-34.
3. Broggini M, Italia C, Colombo T, Marmonti L, Donelli MG. Activity and distribution of IV and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 1984;68:739-47.
4. Di Marco A, Casazza AM, Pratesi G. Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 1977;61:893-4.
5. Ganzina F, Pacciarini MA, De Pietro N. Idarubicin (4-demethoxydaunorubicin): a preliminary overview of preclinical and clinical studies. Invest New Drugs 1986;4:85-105.
6. Casazza AM. Experimental evaluation of anthracycline analogs. Cancer Treat Rep 1979;63:835-44.
7. Gillies HC, Herriott D, Liang R, Ohashi K, Rogers HJ, Harper PG, et al. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 1987;23:303-10.
8. Lu K, Savaraj N, Kavanagh J, Feun LG, Burgess M, Bodey GP, et al. Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). Cancer Chemother Pharmacol 1986;17:143-8.
9. Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, et.al. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 1983; 43:6096-101.
10. Smith D, Margison J, Lucas SB, Wilkinson PM, Howell A. Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. Cancer Chemother Pharmacol 1987;19: 138-43.
11. Zanette L, Zucchetti M, Freshi A, Erranti D, Tirelli V, D'Incalci M. Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemother Pharmacol 1990; 25:445-8.
12. Tan C, Hancock C, Steinherz P, Bacha P, Steinherz L, Luks E, et al. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Cancer Res 1987;47:2990-5.
13. Casazza A, Barbieri B, Fumagalli A, Geroni M. Biologic activity of 4-demethoxy 13-dehydrodaunorubicin. Proc AACR 1983;24:251.
14. Speth PA, Minderman H, Haanen C. Idarubicin v. daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol 1989;16:2-9.
15. Reid J, Pendergrass T, Krailo M, Hammond G, Ames M. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children's Cancer Study Group report. Cancer Res 1990;50:6525-8.
16. Feig S, Ames M, Sather H, Steinherz L, Reid J, Trigg M, et al. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group. Med Pediatr Oncol 1996;27:505-14.
17. Chaing MN, Therneau TM, Wieand HS, Cha AA. Designs for group sequential phase II clinical trials. Biometrics 1987;43: 865-74.